安罗替尼联合^(131)I治疗分化型甲状腺癌51例效果及对患者疲乏程度、红细胞参数的影响  

Effect of Anlotinib Combined with ^(131)I in the Treatment of 51 Cases of Differentiated Thyroid Carcinoma and Its Effects on Fatigue and Erythrocyte Parameters

作　　者：李静娟 LI Jingjuan(Anyang Cancer Hospital,Anyang Henan 455000,China)

机构地区：[1]安阳市肿瘤医院,河南安阳455000

出　　处：《药品评价》2023年第10期1218-1221,共4页Drug Evaluation

摘　　要：目的探讨安罗替尼联合^(131)I治疗分化型甲状腺癌(DTC)的效果及对患者疲乏程度、红细胞参数的影响。方法以随机数字表法将安阳市肿瘤医院2020年1月至2022年12月确诊的102例DTC患者分为研究组、参照组,各51例。参照组行^(131)I治疗,研究组行安罗替尼联合^(131)I治疗。比较两组临床疗效,治疗前后疲乏状况评分(CFS),甲状腺功能[促甲状腺激素(TSH)、甲状腺球蛋白(TG)、抗甲状腺球蛋白抗体(TgAB)],红细胞参数[红细胞计数(RBC)、血红蛋白(HBG)、红细胞沉降率(ESR)],细胞免疫功能指标(NK、CD4^(+)/CD8^(+)、CD4^(+)、CD8^(+))。结果研究组总缓解率84.31%高于参照组66.67%(P<0.05)。治疗后,研究组CFS各维度评分均低于参照组(P<0.05);研究组TSH、TG、TgAB水平均低于参照组(P<0.05);研究组RBC、HBG、ESR水平高于参照组(P<0.05);研究组NK、CD4^(+)/CD8^(+)、CD4^(+)、CD8^(+)水平高于参照组(P<0.05)。结论安罗替尼联合^(131)I治疗DTC效果显著,可降低患者疲乏程度,抑制肿瘤细胞生长,对机体红细胞参数无明显影响,利于病情转归。Objective To investigate the efficacy of anlotinib combined with ^(131)I in the treatment of differentiated thyroid cancer(DTC)and its impact on fatigue and erythrocyte parameters.Methods 102 patients diagnosed with DTC in Anyang Cancer Hospital from January 2020 to December 2022 were divided into study group and reference group with 51 cases in each group by random number table method.The reference group was treated with ^(131)I,and the study group was treated with anlotinib combined with ^(131)I.Compare the clinical efficacy of the two groups,as well as fatigue score(CFS),thyroid function[thyroid stimulating hormone(TSH),thyroglobulin(TG),antithyroglobulin antibody(TgAB)],red blood cell parameters[Red blood cell count(RBC),hemoglobin(HBG),erythrocyte sedimentation rate(ESR)],and cellular immune function indicators(NK,CD4^(+)/CD8^(+),CD4^(+),CD8^(+))before and after treatment.Results The total remission rate of the study group(84.31%)was higher than that of the control group(66.67%)(P<0.05).After treatment,the score of CFS in each dimension of the study group was lower than that of the control group(P<0.05);the levels of TSH,TG and TgAB in the study group were lower than those in the control group(P<0.05);RBC,HBG and ESR levels in the study group were higher than those in the reference group(P<0.05);the levels of NK,CD4^(+)/CD8^(+),CD4^(+)and CD8^(+)in the study group were higher than those in the reference group(P<0.05).Conclusion Anlotinib combined with ^(131)I has a significant effect on the treatment of DTC,which can reduce the fatigue degree of patients and inhibit the growth of tumor cells.It has no obvious effect on the erythrocyte parameters,which is conducive to the outcome of the disease.

关 键 词：甲状腺肿瘤 安罗替尼 ^(131)I 免疫球蛋白类 甲状腺刺激 

分 类 号：R736.1[医药卫生—肿瘤]